title: Targeted therapies in metastatic renal cancer in 2009.
abstract: The development of targeted molecules in renal carcinogenesis changed the therapeutic approaches of treatment for metastatic clear cell renal cell carcinoma. Four available drugs are currently available, i.e. bevacizumab, sunitinib, sorafenib and temsirolimus, but other molecules and combined therapy are under investigation. In this review we assess published reports of these targeted therapies and discuss the novel promising molecules targeting vascular endothelial growth factor and its receptors, the mammalian target of rapamycin and epithelial growth factor cascade.
authors.affiliation: Departments of Urology and Oncology, INSERM U955Eq07, CHU Mondor Assistance Publique des Hopitaux de Paris, Créteil, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Bastien
authors.forename: Stéphane
authors.initials: S
authors.lastname: Culine
authors.forename: Bernard
authors.initials: B
authors.lastname: Paule
authors.forename: Souhil
authors.initials: S
authors.lastname: Ledbai
authors.forename: Jean Jacques
authors.initials: JJ
authors.lastname: Patard
authors.forename: Alexandre
authors.initials: A
authors.lastname: de la Taille